Home Events Hereditary Colon Cancer

Hereditary Colon Cancer


April 21 2021


10:00 am - 11:30 am


  • Dr Aaron Pollett
    Dr Aaron Pollett

    Dr. Aaron Pollett is the Provincial Head, Pathology and Laboratory Medicine Program at Cancer Care Ontario. He is an Anatomic Pathologist and Co-Director of the Division of Diagnostic Medical Genetics at Mount Sinai Hospital and an associate professor in the department of Laboratory Medicine and Pathobiology at the University of Toronto.

    Dr. Pollett has a specialty interest in gastrointestinal pathology and pathology informatics with a Master’s Degree from the Department of Health Policy, Management and Evaluation, University of Toronto. He is the review pathologist for the Familial Gastrointestinal Cancer Registry (FGICR) and the Ontario Familial Colon Cancer Registry (OFCCR), tumour based registries constructed to analyze the genetic basis of gastrointestinal cancers. In his various roles, Dr. Pollett oversees the molecular analysis of solid cancers as well as the development and implementation of new molecular biomarkers

  • Dr Harriet Feilotter
    Dr Harriet Feilotter

    Harriet Feilotter, PhD, FCCMG, FACMG
    Professor, Dept of Pathology and Molecular Medicine, Queen’s University
    Service Chief, Laboratory Genetics and Director, Molecular Diagnostics, Kingston Health Sciences Centre

    Dr. Feilotter is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, where she maintains an active program dedicated to the assessment of methods for biomarker validation and to the transfer of clinically actionable molecular information to the clinical setting. She has a special interest in the integration of platforms designed to support studies of human biomarkers. Her roles as Service Chief of Kingston Health Sciences Center’s Laboratory Genetics and Director of the Queen’s Genomics facility allow her to focus on methods to bridge the gap between research and clinical application of biomarker findings.


• Formulate an appropriate testing plan for hereditary colon cancers
• Interpret information relating to genetic variants to determine pathogenicity
• Integrate molecular results into a final pathology diagnosis for hereditary colon cancer


Molecular investigation of hereditary colon cancer requires an understanding of genomic technologies, as well as the data derived from them, to allow comprehensive assessment of cases. This workshop will focus on specific platforms and approaches used to determine the underlying genomic variations that may be identified in common hereditary colon cancers. The interactive session will allow participants the opportunity to engage in interpretation of assay results from a variety of platforms.